Depemokimab vs Mepolizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: IL-5 · full Asthma pipeline

Depemokimab

Marketed by GlaxoSmithKline

Approved in Asthmamonoclonal antibody
Partial signal

NCT04718389 · Phase 3 · completed

This was a large randomized, double-blind, active-controlled trial comparing depemokimab with mepolizumab or benralizumab, using the clinically meaningful primary endpoint of annualized clinically significant asthma exacerbations. The primary results were 0.57 versus 0.49 exacerbations per participant-year (rate ratio 1.16, 95% CI 0.98–1.38; p=0.079), but the record does not provide the non-inferiority margin, so it is not possible to confirm that the primary endpoint was met.

Next expected readout: February 2027 · NCT07828327 (registry estimate)

Reported efficacy

Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58) (met)

Result source: NCT04719832

Mepolizumab · Nucala

Marketed by GlaxoSmithKline

Approved in Asthmamonoclonal antibody
Weak signal

NCT01691859 · Phase 3 · completed

This was an open-label, single-arm long-term extension of the prior MEA112997 trial, enrolling 347 participants who had received at least two doses in that study. Because there was no randomization, blinding, or control group, the primary safety endpoint was descriptive rather than a comparative efficacy test, although the explicit extension design provides follow-up evidence beyond the original randomized trial. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants Who Experienced On-treatment Adverse Events (AE) and On-treatment Serious Adverse Events (SAE)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66 (met)

Result source: NCT01691508

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDepemokimabMepolizumab
Severe exacerbations, annualised rate0.6 vs 1.1−0.5 vs placebowk 52 · n 252NCT04718103
1 other result
  • 0.5 vs 1.1 wk 52 · n 249 · Phase 3 · primary NCT04719832
0.5 vs 1.3−0.9 vs placebo100 mg · wk 52 · n 149NCT03562195
5 other results
  • 0.8 vs 1.7 100 mg SC · wk 32 · n 194 · Phase 3 · primary NCT01691521
  • 0.9 vs 1.7 75 mg IV · wk 32 · n 191 · Phase 3 · primary NCT01691521
  • 1.2 vs 2.4 75 mg IV · wk 52 · n 153 · Phase 2 · primary NCT01000506
  • 1.1 vs 2.4 750 mg IV · wk 52 · n 156 · Phase 2 · primary NCT01000506
  • 1.5 vs 2.4 250 mg IV · wk 52 · n 152 · Phase 2 · primary NCT01000506
Trough FEV1, change0.2 vs 0.2+0.1 vs placebowk 52 · n 239NCT04718103—Not reported
ACQ-5, change-0.8 vs -0.7−0.1 vs placebowk 52 · n 246NCT04718103
1 other result
  • -0.8 vs -0.8 wk 52 · n 241 · Phase 3 · secondary NCT04719832
-0.8 vs -0.4−0.4 vs placebo100 mg · wk 24 · n 266NCT02281318
OCS dose reduction—Trial running · NCT06979323-50% vs 0%−50 vs placebo100 mg SC · wk 24 · n 69NCT01691508
1 other result

Severe exacerbations, annualised rate

Depemokimab
0.6 vs 1.1−0.5 vs placebowk 52 · n 252NCT04718103
1 other result
  • 0.5 vs 1.1 wk 52 · n 249 · Phase 3 · primary NCT04719832
Mepolizumab
0.5 vs 1.3−0.9 vs placebo100 mg · wk 52 · n 149NCT03562195
5 other results
  • 0.8 vs 1.7 100 mg SC · wk 32 · n 194 · Phase 3 · primary NCT01691521
  • 0.9 vs 1.7 75 mg IV · wk 32 · n 191 · Phase 3 · primary NCT01691521
  • 1.2 vs 2.4 75 mg IV · wk 52 · n 153 · Phase 2 · primary NCT01000506
  • 1.1 vs 2.4 750 mg IV · wk 52 · n 156 · Phase 2 · primary NCT01000506
  • 1.5 vs 2.4 250 mg IV · wk 52 · n 152 · Phase 2 · primary NCT01000506

Trough FEV1, change

Depemokimab
0.2 vs 0.2+0.1 vs placebowk 52 · n 239NCT04718103
Mepolizumab
—Not reported

ACQ-5, change

Depemokimab
-0.8 vs -0.7−0.1 vs placebowk 52 · n 246NCT04718103
1 other result
  • -0.8 vs -0.8 wk 52 · n 241 · Phase 3 · secondary NCT04719832
Mepolizumab
-0.8 vs -0.4−0.4 vs placebo100 mg · wk 24 · n 266NCT02281318

OCS dose reduction

Depemokimab
—Trial running · NCT06979323
Mepolizumab
-50% vs 0%−50 vs placebo100 mg SC · wk 24 · n 69NCT01691508
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. Depemokimab: 12 of 12 rows · Mepolizumab: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDepemokimab
Rows use multiple source trials
Mepolizumab
Rows use multiple source trials
ACQ-5
absolute change · score
No placebo or comparator arm
0.03 score100mg SCa,b,c
NCT04718389 · Phase 3 · combination · Asthma · phase 3
-0.33 score @ 168wk100 mg SCa,b,c
NCT02135692 · Phase 3 · registry result, not featured evidence
Exacerbation Hospitalization ED Rate Annualized
event rate · per year
0.05 vs 0.11 placebo per year @ 52wkd,a,b
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
0.17 vs 0.43 placebo per year @ 52wk75 mg IVe,d,a,b
NCT01000506 · Phase 2
show 2 more doses
0.22 vs 0.43 placebo per year @ 52wk750 mg IV
NCT01000506 · Phase 2
0.25 vs 0.43 placebo per year @ 52wk250 mg IV
NCT01000506 · Phase 2
FEV1
absolute change · L
0.16 vs 0.16 placebo L @ 52wkd,a,b
NCT04719832 · Phase 3
0.121 vs 0.06 placebo L @ 52wk*75 mg IVe,d,a,b
NCT01000506 · Phase 2 · converted to L from 121 mL as posted
show 5 more doses
0.036 vs -0.009 placebo L @ 52wk*75 mg IV
NCT01000506 · Phase 2 · converted to L from 36 mL as posted
0.115 vs 0.06 placebo L @ 52wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 115 mL as posted
0.069 vs -0.009 placebo L @ 52wk*750 mg IV
NCT01000506 · Phase 2 · converted to L from 69 mL as posted
0.14 vs 0.06 placebo L @ 52wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 140 mL as posted
0.08 vs -0.009 placebo L @ 52wk*250 mg IV
NCT01000506 · Phase 2 · converted to L from 80 mL as posted
FEV1
absolute change · L
Extension (open-label)
No placebo or comparator arm
-0.004 L @ 52wk100 mg SCe,a,b,f
NCT05243680 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.036 L @ 52wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.023 L @ 228wk*100 mga,b,f
NCT01691859 · Phase 3 · monotherapy · converted to L from -23 mL as posted
Severe Exacerbation Rate Annualized
event rate · per year
No placebo or comparator arm
0.57 per year @ 52wk100mg SCa,b
NCT04718389 · Phase 3 · combination · Asthma · phase 3
0.93 per year @ 52wk100 mg SCa,b
NCT01842607 · Phase 3 · registry result, not featured evidence
Severe Exacerbation Rate Annualized
event rate · per year
Extension (open-label)
No placebo or comparator arm
0.55 per year @ 52wk100 mg SCe,a,b,c
NCT05243680 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.58 per year @ 52wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
0.68 per year100 mga,b,c
NCT01691859 · Phase 3 · monotherapy
SGRQ Total
absolute change · score
-14.8 vs -12.49 placebo score @ 52wka,b
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
1 other source trial
-13.03 vs -9.67 placebo score @ 52wk
NCT04719832 · Phase 3
-14.29 vs -7.2 placebo score @ 52wk100 mga,b
NCT03562195 · Phase 3 · registry result, not featured evidence
SGRQ Total
absolute change · score
No placebo or comparator arm
-0.69 score100mg SCg,a,b,c
NCT04718389 · Phase 3 · combination · Asthma · phase 3
-19 score @ 32wk100 mg SCg,a,b,c
NCT02654145 · Phase 4 · registry result, not featured evidence
Dropout rate
11.2%100mg SCh
NCT04718389 · Phase 3 · combination · Asthma · phase 3
show 13 more results
11.4%
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
8.5%
NCT04719832 · Phase 3
5.6%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
7%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
1.4%Depemokimab Via Autoinjector
NCT05602025 · Phase 1 · registry result, not featured evidence
1.4%Depemokimab Via SSD
NCT05602025 · Phase 1 · registry result, not featured evidence
0%100mg
NCT05140200 · Phase 1 · registry result, not featured evidence
10%300mg
NCT05140200 · Phase 1 · registry result, not featured evidence
—100mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—300mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—30mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—10mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—2mg
NCT03287310 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone100 mgi
NCT01691859 · Phase 3 · monotherapy
show 37 more results
—Mepolizumab
NCT01691859 · Phase 3 · monotherapy
15.7%75 mg IV
NCT01000506 · Phase 2
14.7%750 mg IV
NCT01000506 · Phase 2
13.8%250 mg IV
NCT01000506 · Phase 2
—100 mg SC
NCT01691508 · Phase 3
2.1%100 mg
NCT04823585 · Phase 4 · registry result, not featured evidence
0%
NCT04765722 · Phase 4 · registry result, not featured evidence
10%100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
4.8%100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
2.7%100 mg
NCT03562195 · Phase 3 · registry result, not featured evidence
3.6%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
1.3%
NCT03099096 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone100 mg SC
NCT02135692 · Phase 3 · registry result, not featured evidence
0%Liquid Autoinjector
NCT03014674 · Phase 3 · registry result, not featured evidence
0%Liquid Safety Syringe
NCT03014674 · Phase 3 · registry result, not featured evidence
1.2%Lyophilized Vial
NCT03014674 · Phase 3 · registry result, not featured evidence
1.8%
NCT03021304 · Phase 3 · registry result, not featured evidence
1.8%100 mg
NCT02281318 · Phase 3 · registry result, not featured evidence
—100 mg SC
NCT02281318 · Phase 3 · registry result, not featured evidence
10.1%100 mg SC
NCT01842607 · Phase 3 · registry result, not featured evidence
4.6%100 mg SC
NCT01691521 · Phase 3 · registry result, not featured evidence
8.4%75 mg IV
NCT01691521 · Phase 3 · registry result, not featured evidence
13.7%
NCT03292588 · Phase 2 · registry result, not featured evidence
0%100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40/100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
15.4%40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
0%75 mg IV
NCT01366521 · Phase 2 · registry result, not featured evidence
8.7%250 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
6.7%125 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
73.7%
NCT00802438 · Phase na · registry result, not featured evidence
Discontinued due to AEs
0.8%100mg SCh
NCT04718389 · Phase 3 · combination · Asthma · phase 3
show 13 more results
0.4%
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
0%
NCT04719832 · Phase 3
0.2%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
0.5%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
—Depemokimab Via Autoinjector
NCT05602025 · Phase 1 · registry result, not featured evidence
—Depemokimab Via SSD
NCT05602025 · Phase 1 · registry result, not featured evidence
—100mg
NCT05140200 · Phase 1 · registry result, not featured evidence
—300mg
NCT05140200 · Phase 1 · registry result, not featured evidence
—100mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—300mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—30mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—10mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—2mg
NCT03287310 · Phase 1 · registry result, not featured evidence
5.5%100 mgi
NCT01691859 · Phase 3 · monotherapy
show 37 more results
—Mepolizumab
NCT01691859 · Phase 3 · monotherapy
3.3%75 mg IV
NCT01000506 · Phase 2
5.8%750 mg IV
NCT01000506 · Phase 2
5.3%250 mg IV
NCT01000506 · Phase 2
—100 mg SC
NCT01691508 · Phase 3
—100 mg
NCT04823585 · Phase 4 · registry result, not featured evidence
—
NCT04765722 · Phase 4 · registry result, not featured evidence
1%100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
—100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT03562195 · Phase 3 · registry result, not featured evidence
0.3%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
0.6%
NCT03099096 · Phase 3 · registry result, not featured evidence
0.9%100 mg SC
NCT02135692 · Phase 3 · registry result, not featured evidence
—Liquid Autoinjector
NCT03014674 · Phase 3 · registry result, not featured evidence
—Liquid Safety Syringe
NCT03014674 · Phase 3 · registry result, not featured evidence
—Lyophilized Vial
NCT03014674 · Phase 3 · registry result, not featured evidence
—
NCT03021304 · Phase 3 · registry result, not featured evidence
0.7%100 mg
NCT02281318 · Phase 3 · registry result, not featured evidence
—100 mg SC
NCT02281318 · Phase 3 · registry result, not featured evidence
1.7%100 mg SC
NCT01842607 · Phase 3 · registry result, not featured evidence
0.5%100 mg SC
NCT01691521 · Phase 3 · registry result, not featured evidence
0%75 mg IV
NCT01691521 · Phase 3 · registry result, not featured evidence
—
NCT03292588 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40/100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
—40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
0%75 mg IV
NCT01366521 · Phase 2 · registry result, not featured evidence
0%250 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
0%125 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
—
NCT00802438 · Phase na · registry result, not featured evidence
Serious AEs
9.4%100mg SCh
NCT04718389 · Phase 3 · combination · Asthma · phase 3
show 13 more results
7.6%
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
6%
NCT04719832 · Phase 3
9.1%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
10%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
2.9%Depemokimab Via Autoinjector
NCT05602025 · Phase 1 · registry result, not featured evidence
0%Depemokimab Via SSD
NCT05602025 · Phase 1 · registry result, not featured evidence
0%100mg
NCT05140200 · Phase 1 · registry result, not featured evidence
0%300mg
NCT05140200 · Phase 1 · registry result, not featured evidence
0%100mg
NCT03287310 · Phase 1 · registry result, not featured evidence
0%300mg
NCT03287310 · Phase 1 · registry result, not featured evidence
0%30mg
NCT03287310 · Phase 1 · registry result, not featured evidence
0%10mg
NCT03287310 · Phase 1 · registry result, not featured evidence
0%2mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—100 mgi
NCT01691859 · Phase 3 · monotherapy
show 37 more results
22.8%Mepolizumab
NCT01691859 · Phase 3 · monotherapy
13.1%75 mg IV
NCT01000506 · Phase 2
12.2%750 mg IV
NCT01000506 · Phase 2
15.8%250 mg IV
NCT01000506 · Phase 2
1.4%100 mg SC
NCT01691508 · Phase 3
4.3%100 mg
NCT04823585 · Phase 4 · registry result, not featured evidence
0%
NCT04765722 · Phase 4 · registry result, not featured evidence
3%100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
11%100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
12.1%100 mg
NCT03562195 · Phase 3 · registry result, not featured evidence
2.3%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
6.3%100mg
NCT02555371 · Phase 3 · registry result, not featured evidence
—100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
8.9%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
11.9%100mg SC
NCT02555371 · Phase 3 · registry result, not featured evidence
2.5%
NCT03099096 · Phase 3 · registry result, not featured evidence
24.8%100 mg SC
NCT02135692 · Phase 3 · registry result, not featured evidence
0%Liquid Autoinjector
NCT03014674 · Phase 3 · registry result, not featured evidence
0%Liquid Safety Syringe
NCT03014674 · Phase 3 · registry result, not featured evidence
0%Lyophilized Vial
NCT03014674 · Phase 3 · registry result, not featured evidence
5.4%
NCT03021304 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02281318 · Phase 3 · registry result, not featured evidence
5.5%100 mg SC
NCT02281318 · Phase 3 · registry result, not featured evidence
14.4%100 mg SC
NCT01842607 · Phase 3 · registry result, not featured evidence
8.2%100 mg SC
NCT01691521 · Phase 3 · registry result, not featured evidence
7.3%75 mg IV
NCT01691521 · Phase 3 · registry result, not featured evidence
2.7%
NCT03292588 · Phase 2 · registry result, not featured evidence
10%100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
20%100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
25%40/100 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
19.2%40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
25%40 mg SC
NCT02377427 · Phase 2 · registry result, not featured evidence
0%75 mg IV
NCT01366521 · Phase 2 · registry result, not featured evidence
0%250 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
0%125 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg SC
NCT01366521 · Phase 2 · registry result, not featured evidence
0%
NCT00802438 · Phase na · registry result, not featured evidence
Most frequent reported AEs
100mg SCh
nasopharyngitis 20.6%
covid-19 18.3%
upper respiratory tract infection 11.4%
NCT04718389 · Phase 3 · combination · Asthma · phase 3
show 13 more results
covid-19 14.3% (placebo 14.7%)
nasopharyngitis 13.1% (placebo 20.9%)
upper respiratory tract infection 8.4% (placebo 4.7%)
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
covid-19 20.4% (placebo 20.5%)
nasopharyngitis 11.6% (placebo 18.9%)
upper respiratory tract infection 10% (placebo 10.6%)
NCT04719832 · Phase 3
100 mg SC
nasopharyngitis 13.8%
upper respiratory tract infection 10.7%
covid-19 6.7%
NCT05243680 · Phase 3 · registry result, not featured evidence
100 mg SC
upper respiratory tract infection 11.9%
nasopharyngitis 10%
covid-19 7.1%
NCT05243680 · Phase 3 · registry result, not featured evidence
headache 8.6%
injection site swelling 5.7%
abdominal pain 4.3%
NCT05602025 · Phase 1 · registry result, not featured evidence
headache 10%
injection site bruising 4.3%
nausea 4.3%
NCT05602025 · Phase 1 · registry result, not featured evidence
100mg
blood creatine phosphokinase increased 80%
blood uric acid increased 30%
neutrophil count increased 20%
NCT05140200 · Phase 1 · registry result, not featured evidence
300mg
albumin urine present 50%
blood creatine phosphokinase increased 40%
blood uric acid increased 40%
NCT05140200 · Phase 1 · registry result, not featured evidence
100mg
nasopharyngitis 55.6% (placebo 16.7%)
headache 33.3% (placebo 0%)
back pain 22.2% (placebo 8.3%)
NCT03287310 · Phase 1 · registry result, not featured evidence
300mg
headache 33.3% (placebo 0%)
nasopharyngitis 33.3% (placebo 16.7%)
epistaxis 16.7% (placebo 0%)
NCT03287310 · Phase 1 · registry result, not featured evidence
30mg
nasopharyngitis 33.3% (placebo 16.7%)
arthropod sting 22.2% (placebo 0%)
dry skin 22.2% (placebo 0%)
NCT03287310 · Phase 1 · registry result, not featured evidence
10mg
dyspepsia 33.3% (placebo 0%)
rib fracture 33.3% (placebo 0%)
seasonal allergy 33.3% (placebo 16.7%)
NCT03287310 · Phase 1 · registry result, not featured evidence
2mg
nasopharyngitis 33.3% (placebo 16.7%)
diarrhoea 16.7% (placebo 0%)
headache 16.7% (placebo 0%)
NCT03287310 · Phase 1 · registry result, not featured evidence
i
viral upper respiratory tract infection 48.7%
headache 28.5%
upper respiratory tract infection 23.3%
NCT01691859 · Phase 3 · monotherapy
show 34 more results
75 mg IV
nasopharyngitis 22.2% (placebo 15.5%)
headache 20.9% (placebo 17.4%)
bronchitis 10.5% (placebo 9.7%)
NCT01000506 · Phase 2
750 mg IV
headache 20.5% (placebo 17.4%)
nasopharyngitis 18.6% (placebo 15.5%)
infusion related reaction 12.2% (placebo 6.5%)
NCT01000506 · Phase 2
250 mg IV
nasopharyngitis 21.7% (placebo 15.5%)
headache 21.1% (placebo 17.4%)
upper respiratory tract infection 11.2% (placebo 9.7%)
NCT01000506 · Phase 2
100 mg SC
headache 20.3% (placebo 21.2%)
nasopharyngitis 14.5% (placebo 15.2%)
bronchitis 10.1% (placebo 9.1%)
NCT01691508 · Phase 3
100 mg
musculoskeletal 4.3% (placebo 0%)
nausea, headache, dizzines 2.1% (placebo 8.3%)
skin-related symptom 2.1% (placebo 4.2%)
NCT04823585 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 26.7% (placebo 40%)
NCT04765722 · Phase 4 · registry result, not featured evidence
100 mg SC
pyrexia 5%
headache 3%
oropharyngeal pain 3%
NCT04276233 · Phase 4 · registry result, not featured evidence
100 mg SC
headache 28.3%
viral upper respiratory tract infection 16.6%
bronchitis 13.1%
NCT02654145 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 40.9% (placebo 41.7%)
asthma 30.2% (placebo 54.3%)
nasopharyngitis 16.8% (placebo 17.9%)
NCT03562195 · Phase 3 · registry result, not featured evidence
100mg SC
nasopharyngitis 4.6% (placebo 17.2%)
abdominal pain 0% (placebo 0%)
arthralgia 0% (placebo 2%)
NCT02555371 · Phase 3 · registry result, not featured evidence
100mg
nasopharyngitis 18.8% (placebo 17.2%)
bronchitis 9.7% (placebo 3.3%)
sinusitis 9% (placebo 6%)
NCT02555371 · Phase 3 · registry result, not featured evidence
100mg SC
nasopharyngitis 20% (placebo 17.2%)
bronchitis 17.8% (placebo 3.3%)
sinusitis 11.1% (placebo 6%)
NCT02555371 · Phase 3 · registry result, not featured evidence
100mg SC
nasopharyngitis 19% (placebo 17.2%)
asthma 8.3% (placebo 9.3%)
bronchitis 8.3% (placebo 3.3%)
NCT02555371 · Phase 3 · registry result, not featured evidence
nasopharyngitis 5.7%
headache 5%
upper respiratory tract infection 3.8%
NCT03099096 · Phase 3 · registry result, not featured evidence
100 mg SC
nasopharyngitis 42.2%
bronchitis 18.9%
upper respiratory tract infection 18.9%
NCT02135692 · Phase 3 · registry result, not featured evidence
headache 11.4%
viral upper respiratory tract infection 3.8%
fatigue 2.5%
NCT03014674 · Phase 3 · registry result, not featured evidence
headache 10%
viral upper respiratory tract infection 7.5%
fatigue 1.3%
NCT03014674 · Phase 3 · registry result, not featured evidence
headache 7.1%
fatigue 5.9%
viral upper respiratory tract infection 2.4%
NCT03014674 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 7.1%
NCT03021304 · Phase 3 · registry result, not featured evidence
100 mg SC
headache 16.5% (placebo 21.2%)
nasopharyngitis 11.4% (placebo 16.5%)
upper respiratory tract infection 6.2% (placebo 5%)
NCT02281318 · Phase 3 · registry result, not featured evidence
100 mg SC
nasopharyngitis 30.1%
upper respiratory tract infection 15.2%
headache 13.4%
NCT01842607 · Phase 3 · registry result, not featured evidence
100 mg SC
headache 20.1% (placebo 17.3%)
nasopharyngitis 17% (placebo 24.1%)
upper respiratory tract infection 12.4% (placebo 14.1%)
NCT01691521 · Phase 3 · registry result, not featured evidence
75 mg IV
headache 24.1% (placebo 17.3%)
nasopharyngitis 23.6% (placebo 24.1%)
upper respiratory tract infection 11.5% (placebo 14.1%)
NCT01691521 · Phase 3 · registry result, not featured evidence
headache 10.3% (placebo 4.9%)
injection site reaction 8.9% (placebo 0%)
vomiting 8.9% (placebo 8.3%)
NCT03292588 · Phase 2 · registry result, not featured evidence
100 mg SC
headache 20%
acne 10%
alanine aminotransferase increased 10%
NCT02377427 · Phase 2 · registry result, not featured evidence
100 mg SC
bronchitis 30%
headache 30%
cough 20%
NCT02377427 · Phase 2 · registry result, not featured evidence
40/100 mg SC
nasopharyngitis 50%
abdominal pain 25%
adrenal suppression 25%
NCT02377427 · Phase 2 · registry result, not featured evidence
40 mg SC
injection site reaction 19.2%
headache 11.5%
nasopharyngitis 11.5%
NCT02377427 · Phase 2 · registry result, not featured evidence
40 mg SC
bronchitis 31.3%
headache 25%
influenza 18.8%
NCT02377427 · Phase 2 · registry result, not featured evidence
75 mg IV
arthralgia 18.2%
asthma 9.1%
back pain 9.1%
NCT01366521 · Phase 2 · registry result, not featured evidence
250 mg SC
headache 8.7%
nasopharyngitis 8.7%
abdominal distension 4.3%
NCT01366521 · Phase 2 · registry result, not featured evidence
125 mg SC
injection site reaction 20%
asthma 6.7%
dermatitis atopic 6.7%
NCT01366521 · Phase 2 · registry result, not featured evidence
12.5 mg SC
asthma 19%
injection site reaction 14.3%
nasopharyngitis 14.3%
NCT01366521 · Phase 2 · registry result, not featured evidence
upper respiratory infection 10.5%
back pain 2.6%
erythema 2.6%
NCT00802438 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dTrial phases differ: Phase 2 versus Phase 3.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 228 weeks versus 52 weeks.
  7. gTrial phases differ: Phase 4 versus Phase 3.
  8. hPopulation comparability has not been reviewed for 12 of these studies.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Depemokimab

FEV1 Trough -0.014 L100mg SC
absolute change · L
No placebo or comparator arm
NCT04718389 · Phase 3 · combination · Asthma · phase 3
FEV1 Trough 0.24 vs 0.184 placebo L @ 52wk
absolute change · L
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
ANSD Weekly Mean -1.18 vs -0.97 placebo score @ 52wk
absolute change · score
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
-1.39 vs -1.3 placebo score @ 52wk
NCT04719832 · Phase 3
ADSD -1.13 vs -0.93 placebo score @ 52wk
absolute change · score
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
-1.33 vs -1.25 placebo score @ 52wk
NCT04719832 · Phase 3
Exacerbation Hospitalization ED Rate Annualized 5 vs 13 placebo Exacerbations @ 52wk
event rate · Exacerbations
NCT04719832 · Phase 3
ACQ-5 -0.28 score @ 4wk100 mg SC
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT05243680 · Phase 3 · registry result, not featured evidence
show 17 more results
-0.16 score @ 4wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.22 score @ 8wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.19 score @ 8wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.28 score @ 12wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.22 score @ 12wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.16 score @ 20wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.16 score @ 20wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.14 score @ 26wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.12 score @ 26wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.23 score @ 28wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.24 score @ 28wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.35 score @ 32wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.25 score @ 32wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.24 score @ 40wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.16 score @ 40wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.15 score @ 52wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-0.11 score @ 52wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
SGRQ Total -5 score @ 26wk100 mg SC
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT05243680 · Phase 3 · registry result, not featured evidence
show 3 more results
-2.62 score @ 26wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-4.75 score @ 52wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
-2.33 score @ 52wk100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence

Mepolizumab

ACQ -0.47 score @ 12wk100 mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01691859 · Phase 3 · monotherapy
show 17 more results
-0.55 score @ 24wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.56 score @ 36wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.55 score @ 48wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.58 score @ 60wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.51 score @ 72wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.54 score @ 84wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.44 score @ 96wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.51 score @ 112wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.66 score @ 124wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.58 score @ 136wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.54 score @ 148wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.59 score @ 164wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.49 score @ 176wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.4 score @ 188wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.45 score @ 200wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.42 score @ 216wk100 mg
NCT01691859 · Phase 3 · monotherapy
-0.47 score @ 228wk100 mg
NCT01691859 · Phase 3 · monotherapy
ACQ -0.53 score100 mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
Follow-up, n=301
NCT01691859 · Phase 3 · monotherapy
Time to First Moderate or Severe Exacerbation 22.8% (n=153) vs 45.2% (n=155) placebo @ 16wk75 mg IV
responder rate · % of participants
NCT01000506 · Phase 2
show 8 more results
38.2% (n=153) vs 60.4% (n=155) placebo @ 32wk75 mg IV
NCT01000506 · Phase 2
48.5% (n=153) vs 69.7% (n=155) placebo @ 52wk75 mg IV
NCT01000506 · Phase 2
18.9% (n=156) vs 45.2% (n=155) placebo @ 16wk750 mg IV
NCT01000506 · Phase 2
39.9% (n=156) vs 60.4% (n=155) placebo @ 32wk750 mg IV
NCT01000506 · Phase 2
50.1% (n=156) vs 69.7% (n=155) placebo @ 52wk750 mg IV
NCT01000506 · Phase 2
26.8% (n=152) vs 45.2% (n=155) placebo @ 16wk250 mg IV
NCT01000506 · Phase 2
45.5% (n=152) vs 60.4% (n=155) placebo @ 32wk250 mg IV
NCT01000506 · Phase 2
58.3% (n=152) vs 69.7% (n=155) placebo @ 52wk250 mg IV
NCT01000506 · Phase 2
Time to First Exacerbation Leading to Hospitalization 3.4% (n=153) vs 8.6% (n=155) placebo @ 16wk75 mg IV
absolute value · percentage points
NCT01000506 · Phase 2
show 8 more results
8.3% (n=153) vs 14.8% (n=155) placebo @ 32wk75 mg IV
NCT01000506 · Phase 2
10.4% (n=153) vs 18.5% (n=155) placebo @ 52wk75 mg IV
NCT01000506 · Phase 2
3.9% (n=156) vs 8.6% (n=155) placebo @ 16wk750 mg IV
NCT01000506 · Phase 2
8% (n=156) vs 14.8% (n=155) placebo @ 32wk750 mg IV
NCT01000506 · Phase 2
12.4% (n=156) vs 18.5% (n=155) placebo @ 52wk750 mg IV
NCT01000506 · Phase 2
6.7% (n=152) vs 8.6% (n=155) placebo @ 16wk250 mg IV
NCT01000506 · Phase 2
15.1% (n=152) vs 14.8% (n=155) placebo @ 32wk250 mg IV
NCT01000506 · Phase 2
15.9% (n=152) vs 18.5% (n=155) placebo @ 52wk250 mg IV
NCT01000506 · Phase 2
Asthma Exacerbation 1.34 vs 2.46 placebo per year @ 52wk75 mg IV
absolute value · per year
NCT01000506 · Phase 2
show 2 more results
1.2 vs 2.46 placebo per year @ 52wk750 mg IV
NCT01000506 · Phase 2
1.49 vs 2.46 placebo per year @ 52wk250 mg IV
NCT01000506 · Phase 2
Time to First Exacerbation 26.1% (n=153) vs 45.9% (n=155) placebo @ 16wk75 mg IV
absolute value · percentage points
NCT01000506 · Phase 2
show 8 more results
41.5% (n=153) vs 60.9% (n=155) placebo @ 32wk75 mg IV
NCT01000506 · Phase 2
52.2% (n=153) vs 70.1% (n=155) placebo @ 52wk75 mg IV
NCT01000506 · Phase 2
19.6% (n=156) vs 45.9% (n=155) placebo @ 16wk750 mg IV
NCT01000506 · Phase 2
40.5% (n=156) vs 60.9% (n=155) placebo @ 32wk750 mg IV
NCT01000506 · Phase 2
50.8% (n=156) vs 70.1% (n=155) placebo @ 52wk750 mg IV
NCT01000506 · Phase 2
27.5% (n=152) vs 45.9% (n=155) placebo @ 16wk250 mg IV
NCT01000506 · Phase 2
45.5% (n=152) vs 60.9% (n=155) placebo @ 32wk250 mg IV
NCT01000506 · Phase 2
58.3% (n=152) vs 70.1% (n=155) placebo @ 52wk250 mg IV
NCT01000506 · Phase 2
ACQ -0.61 vs -0.45 placebo score @ 4wk75 mg IV
absolute change · score
NCT01000506 · Phase 2
show 38 more results
-0.73 vs -0.5 placebo score @ 8wk75 mg IV
NCT01000506 · Phase 2
-0.79 vs -0.63 placebo score @ 12wk75 mg IV
NCT01000506 · Phase 2
-0.8 vs -0.59 placebo score @ 16wk75 mg IV
NCT01000506 · Phase 2
-0.82 vs -0.59 placebo score @ 20wk75 mg IV
NCT01000506 · Phase 2
-0.85 vs -0.66 placebo score @ 24wk75 mg IV
NCT01000506 · Phase 2
-0.81 vs -0.7 placebo score @ 28wk75 mg IV
NCT01000506 · Phase 2
-0.74 vs -0.62 placebo score @ 32wk75 mg IV
NCT01000506 · Phase 2
-0.78 vs -0.6 placebo score @ 36wk75 mg IV
NCT01000506 · Phase 2
-0.76 vs -0.64 placebo score @ 40wk75 mg IV
NCT01000506 · Phase 2
-0.75 vs -0.62 placebo score @ 44wk75 mg IV
NCT01000506 · Phase 2
-0.72 vs -0.63 placebo score @ 48wk75 mg IV
NCT01000506 · Phase 2
-0.75 vs -0.59 placebo score @ 52wk75 mg IV
NCT01000506 · Phase 2
-0.56 vs -0.45 placebo score @ 4wk750 mg IV
NCT01000506 · Phase 2
-0.65 vs -0.5 placebo score @ 8wk750 mg IV
NCT01000506 · Phase 2
-0.72 vs -0.63 placebo score @ 12wk750 mg IV
NCT01000506 · Phase 2
-0.76 vs -0.59 placebo score @ 16wk750 mg IV
NCT01000506 · Phase 2
-0.72 vs -0.59 placebo score @ 20wk750 mg IV
NCT01000506 · Phase 2
-0.79 vs -0.66 placebo score @ 24wk750 mg IV
NCT01000506 · Phase 2
-0.73 vs -0.7 placebo score @ 28wk750 mg IV
NCT01000506 · Phase 2
-0.74 vs -0.62 placebo score @ 32wk750 mg IV
NCT01000506 · Phase 2
-0.76 vs -0.6 placebo score @ 36wk750 mg IV
NCT01000506 · Phase 2
-0.67 vs -0.64 placebo score @ 40wk750 mg IV
NCT01000506 · Phase 2
-0.69 vs -0.62 placebo score @ 44wk750 mg IV
NCT01000506 · Phase 2
-0.68 vs -0.63 placebo score @ 48wk750 mg IV
NCT01000506 · Phase 2
-0.8 vs -0.59 placebo score @ 52wk750 mg IV
NCT01000506 · Phase 2
-0.5 vs -0.45 placebo score @ 4wk250 mg IV
NCT01000506 · Phase 2
-0.6 vs -0.5 placebo score @ 8wk250 mg IV
NCT01000506 · Phase 2
-0.65 vs -0.63 placebo score @ 12wk250 mg IV
NCT01000506 · Phase 2
-0.52 vs -0.59 placebo score @ 16wk250 mg IV
NCT01000506 · Phase 2
-0.61 vs -0.59 placebo score @ 20wk250 mg IV
NCT01000506 · Phase 2
-0.7 vs -0.66 placebo score @ 24wk250 mg IV
NCT01000506 · Phase 2
-0.66 vs -0.7 placebo score @ 28wk250 mg IV
NCT01000506 · Phase 2
-0.76 vs -0.62 placebo score @ 32wk250 mg IV
NCT01000506 · Phase 2
-0.75 vs -0.6 placebo score @ 36wk250 mg IV
NCT01000506 · Phase 2
-0.73 vs -0.64 placebo score @ 40wk250 mg IV
NCT01000506 · Phase 2
-0.77 vs -0.62 placebo score @ 44wk250 mg IV
NCT01000506 · Phase 2
-0.74 vs -0.63 placebo score @ 48wk250 mg IV
NCT01000506 · Phase 2
-0.87 vs -0.59 placebo score @ 52wk250 mg IV
NCT01000506 · Phase 2
OCS Dose 50% Reduction 53.6% (n=69) vs 33.3% (n=66) placebo @ 24wk100 mg SC
event count · % of participants
50 to 100%
NCT01691508 · Phase 3 · converted to % from 37 Participants as posted
OCS Dose 5 mg or Less 53.6% (n=69) vs 31.8% (n=66) placebo @ 24wk100 mg SC
event count · % of participants
<=5 mg/day
NCT01691508 · Phase 3 · converted to % from 37 Participants as posted
OCS Dose 100% Reduction 14.5% (n=69) vs 7.6% (n=66) placebo @ 24wk100 mg SC
event count · % of participants
0 mg/day
NCT01691508 · Phase 3 · converted to % from 10 Participants as posted
OCS Dose Reduction -50% (n=69) vs 0% (n=66) placebo @ 24wk100 mg SC
absolute value · percentage points
NCT01691508 · Phase 3
show 1 more result
83.8% vs 47.7% placebo
NCT00292877 · Phase 2 · sponsor-reported, not registry data
SNOT-22 -14.09 vs -4.37 placebo points @ 16wk100 mg
absolute change · points
NCT04823585 · Phase 4 · registry result, not featured evidence

+ 26 further endpoints in the CSV export.

Chronic Obstructive Pulmonary Disease

Shared mechanism: IL-5 · full Chronic Obstructive Pulmonary Disease pipeline

Depemokimab

Marketed by GlaxoSmithKline

Phase 3 in Chronic Obstructive Pulmonary Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2028 · NCT06961214 (registry estimate)

No aligned efficacy figure on record for this race.

Mepolizumab · Nucala

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasemonoclonal antibody
Partial signal

NCT01463644 · Phase 3 · completed

Participants were randomly assigned and quadruple-blinded to mepolizumab or placebo, but only 18 people were enrolled. The primary endpoint was a sputum eosinophil biomarker rather than a clinical outcome, and the registry does not state whether the between-group difference was statistically significant, so the result is unclear.

Next expected readout: February 2028 · NCT07749001 (registry estimate)

Reported efficacy

Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15) (met)

Result source: NCT04133909

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDepemokimabMepolizumab
Moderate or severe exacerbations, annualised rate—Trial running · NCT069612140.8 vs 1.0−0.2 vs placebo100 mg · wk 104 · n 403NCT04133909
4 other results
  • 1.4 vs 1.7 100 mg · wk 52 · n 233 · Phase 3 · primary NCT02105948
  • 1.5 vs 1.5 100 mg · wk 52 · n 417 · Phase 3 · primary NCT02105948
  • 1.2 vs 1.5 100 mg SC · wk 52 · n 223 · Phase 3 · primary NCT02105961
  • 1.3 vs 1.5 300 mg SC · wk 52 · n 225 · Phase 3 · primary NCT02105961
Trough FEV1, change—Trial running · NCT06961214—Not reported
SGRQ total, change—Trial running · NCT06961214-2.8 vs -3+0.2 vs placebo100 mg · wk 52 · n 226NCT02105948
9 other results
  • -3.2 vs -4 100 mg · wk 52 · n 397 · Phase 3 · secondary NCT02105948
  • -5 vs -3.1 100 mg SC · wk 52 · n 218 · Phase 3 · secondary NCT02105961
  • -3.3 vs -3.1 300 mg SC · wk 52 · n 219 · Phase 3 · secondary NCT02105961
  • 60.7 vs 62.4 wk 48 · n 111 · Phase 2/3 · secondary NCT04075331
  • 61.2 vs 60.4 wk 36 · n 111 · Phase 2/3 · secondary NCT04075331
  • 64.3 vs 61.7 wk 24 · n 111 · Phase 2/3 · secondary NCT04075331
  • 64.3 vs 63.3 wk 12 · n 111 · Phase 2/3 · secondary NCT04075331
  • 64.3 vs 64.6 wk 8 · n 111 · Phase 2/3 · secondary NCT04075331
  • 65.5 vs 66.2 wk 4 · n 111 · Phase 2/3 · secondary NCT04075331
TDI focal score—Trial running · NCT06961214—Not reported

Moderate or severe exacerbations, annualised rate

Depemokimab
—Trial running · NCT06961214
Mepolizumab
0.8 vs 1.0−0.2 vs placebo100 mg · wk 104 · n 403NCT04133909
4 other results
  • 1.4 vs 1.7 100 mg · wk 52 · n 233 · Phase 3 · primary NCT02105948
  • 1.5 vs 1.5 100 mg · wk 52 · n 417 · Phase 3 · primary NCT02105948
  • 1.2 vs 1.5 100 mg SC · wk 52 · n 223 · Phase 3 · primary NCT02105961
  • 1.3 vs 1.5 300 mg SC · wk 52 · n 225 · Phase 3 · primary NCT02105961

Trough FEV1, change

Depemokimab
—Trial running · NCT06961214
Mepolizumab
—Not reported

SGRQ total, change

Depemokimab
—Trial running · NCT06961214
Mepolizumab
-2.8 vs -3+0.2 vs placebo100 mg · wk 52 · n 226NCT02105948
9 other results
  • -3.2 vs -4 100 mg · wk 52 · n 397 · Phase 3 · secondary NCT02105948
  • -5 vs -3.1 100 mg SC · wk 52 · n 218 · Phase 3 · secondary NCT02105961
  • -3.3 vs -3.1 300 mg SC · wk 52 · n 219 · Phase 3 · secondary NCT02105961
  • 60.7 vs 62.4 wk 48 · n 111 · Phase 2/3 · secondary NCT04075331
  • 61.2 vs 60.4 wk 36 · n 111 · Phase 2/3 · secondary NCT04075331
  • 64.3 vs 61.7 wk 24 · n 111 · Phase 2/3 · secondary NCT04075331
  • 64.3 vs 63.3 wk 12 · n 111 · Phase 2/3 · secondary NCT04075331
  • 64.3 vs 64.6 wk 8 · n 111 · Phase 2/3 · secondary NCT04075331
  • 65.5 vs 66.2 wk 4 · n 111 · Phase 2/3 · secondary NCT04075331

TDI focal score

Depemokimab
—Trial running · NCT06961214
Mepolizumab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Depemokimab: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Depemokimab: 0 of 4 rows · Mepolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricMepolizumab
Dropout rate
0%a
NCT01463644 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 6 more results
16.1%100 mg
NCT04133909 · Phase 3
8.6%100 mg
NCT02105948 · Phase 3
14.7%100 mg
NCT02105948 · Phase 3
7.6%100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
13.3%300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
26.9%
NCT04075331 · Phase 2/3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01463644 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 6 more results
1%100 mg
NCT04133909 · Phase 3
3%100 mg
NCT02105948 · Phase 3
6%100 mg
NCT02105948 · Phase 3
3.1%100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
5.8%300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
—
NCT04075331 · Phase 2/3 · registry result, not featured evidence
Serious AEs
25%a
NCT01463644 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 6 more results
25.1%100 mg
NCT04133909 · Phase 3
27.9%100 mg
NCT02105948 · Phase 3
27.2%100 mg
NCT02105948 · Phase 3
25.6%100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
26.7%300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
1.7%
NCT04075331 · Phase 2/3 · registry result, not featured evidence
Most frequent reported AEs
a
infective bronchitis 37.5% (placebo 40%)
urinary tract infection 12.5% (placebo 0%)
NCT01463644 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 6 more results
100 mg
covid-19 11.9% (placebo 11.7%)
nasopharyngitis 10.2% (placebo 8.7%)
headache 7.9% (placebo 7%)
NCT04133909 · Phase 3
100 mg
nasopharyngitis 16.3% (placebo 14%)
headache 10.3% (placebo 13.5%)
back pain 7.3% (placebo 7%)
NCT02105948 · Phase 3
100 mg
nasopharyngitis 14.1% (placebo 14%)
headache 9.8% (placebo 13.5%)
back pain 8.7% (placebo 7%)
NCT02105948 · Phase 3
100 mg SC
nasopharyngitis 17.5% (placebo 21.2%)
headache 15.2% (placebo 8.8%)
upper respiratory tract infection 7.2% (placebo 8.8%)
NCT02105961 · Phase 3 · registry result, not featured evidence
300 mg SC
nasopharyngitis 17.8% (placebo 21.2%)
headache 9.8% (placebo 8.8%)
back pain 7.6% (placebo 4.9%)
NCT02105961 · Phase 3 · registry result, not featured evidence
diarrhoea 10.2% (placebo 7.6%)
covid-19 6.8% (placebo 5.9%)
fall 6.8% (placebo 7.6%)
NCT04075331 · Phase 2/3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Mepolizumab

Major Exacerbation Proportion 50% (n=8) vs 70% (n=10) placebo @ 24wk
responder rate · % of participants
NCT01463644 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 · converted to % from 4 participants as posted
Moderate or Severe Exacerbation Rate Annualized 0.8 vs 1.01 placebo per year @ 104wk100 mg
event rate · per year
NCT04133909 · Phase 3
show 4 more results
1.4 vs 1.71 placebo per year @ 52wk100 mg
NCT02105948 · Phase 3
1.49 vs 1.52 placebo per year @ 52wk100 mg
NCT02105948 · Phase 3
1.19 vs 1.49 placebo per year @ 52wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
1.27 vs 1.49 placebo per year @ 52wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
Time to First Exacerbation 11.3% (n=403) vs 15.1% (n=401) placebo @ 8wk100 mg
absolute value · percentage points
NCT04133909 · Phase 3
show 13 more results
21.6% (n=403) vs 25.6% (n=401) placebo @ 16wk100 mg
NCT04133909 · Phase 3
28.3% (n=403) vs 35.4% (n=401) placebo @ 24wk100 mg
NCT04133909 · Phase 3
33.6% (n=403) vs 41.6% (n=401) placebo @ 32wk100 mg
NCT04133909 · Phase 3
39.8% (n=403) vs 47.1% (n=401) placebo @ 40wk100 mg
NCT04133909 · Phase 3
44.9% (n=403) vs 51.4% (n=401) placebo @ 48wk100 mg
NCT04133909 · Phase 3
46.1% (n=403) vs 53.4% (n=401) placebo @ 52wk100 mg
NCT04133909 · Phase 3
46.7% (n=403) vs 54% (n=401) placebo @ 56wk100 mg
NCT04133909 · Phase 3
51.4% (n=403) vs 58.9% (n=401) placebo @ 64wk100 mg
NCT04133909 · Phase 3
55.9% (n=403) vs 60.5% (n=401) placebo @ 72wk100 mg
NCT04133909 · Phase 3
59% (n=403) vs 62.3% (n=401) placebo @ 80wk100 mg
NCT04133909 · Phase 3
60.6% (n=403) vs 64.2% (n=401) placebo @ 88wk100 mg
NCT04133909 · Phase 3
62.3% (n=403) vs 67.2% (n=401) placebo @ 96wk100 mg
NCT04133909 · Phase 3
64.5% (n=403) vs 68.3% (n=401) placebo @ 104wk100 mg
NCT04133909 · Phase 3
CAT 41% (n=391) vs 46% (n=394) placebo @ 52wk100 mg
responder rate · % of participants
NCT04133909 · Phase 3
SGRQ 50% (n=390) vs 46% (n=393) placebo @ 52wk100 mg
responder rate · % of participants
NCT04133909 · Phase 3
E-RS 31% (n=403) vs 34% (n=399) placebo @ 52wk100 mg
responder rate · % of participants
NCT04133909 · Phase 3
Exacerbation Hospitalization ED Rate Annualized 0.13 vs 0.2 placebo per year @ 104wk100 mg
event rate · per year
NCT04133909 · Phase 3
show 4 more results
0.3 vs 0.26 placebo per year @ 52wk100 mg
NCT02105948 · Phase 3
0.29 vs 0.26 placebo per year @ 52wk100 mg
NCT02105948 · Phase 3
0.17 vs 0.28 placebo per year @ 52wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
0.23 vs 0.28 placebo per year @ 52wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
Time to First Moderate or Severe Exacerbation 20.2% (n=233) vs 28.1% (n=229) placebo @ 8wk100 mg
responder rate · % of participants
NCT02105948 · Phase 3
show 27 more results
34.9% (n=233) vs 45.5% (n=229) placebo @ 16wk100 mg
NCT02105948 · Phase 3
45.8% (n=233) vs 53.4% (n=229) placebo @ 24wk100 mg
NCT02105948 · Phase 3
55.3% (n=233) vs 60.9% (n=229) placebo @ 32wk100 mg
NCT02105948 · Phase 3
59.3% (n=233) vs 68.5% (n=229) placebo @ 40wk100 mg
NCT02105948 · Phase 3
62% (n=233) vs 71.8% (n=229) placebo @ 48wk100 mg
NCT02105948 · Phase 3
64.6% (n=233) vs 75.2% (n=229) placebo @ 52wk100 mg
NCT02105948 · Phase 3
23.6% (n=417) vs 25.1% (n=419) placebo @ 8wk100 mg
NCT02105948 · Phase 3
37.4% (n=417) vs 39.8% (n=419) placebo @ 16wk100 mg
NCT02105948 · Phase 3
46.3% (n=417) vs 49.2% (n=419) placebo @ 24wk100 mg
NCT02105948 · Phase 3
54.1% (n=417) vs 57.3% (n=419) placebo @ 32wk100 mg
NCT02105948 · Phase 3
59.7% (n=417) vs 63.8% (n=419) placebo @ 40wk100 mg
NCT02105948 · Phase 3
62.5% (n=417) vs 67.3% (n=419) placebo @ 48wk100 mg
NCT02105948 · Phase 3
65.5% (n=417) vs 71.2% (n=419) placebo @ 52wk100 mg
NCT02105948 · Phase 3
22.9% (n=223) vs 22.6% (n=226) placebo @ 8wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
36% (n=223) vs 40.7% (n=226) placebo @ 16wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
42.4% (n=223) vs 51.1% (n=226) placebo @ 24wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
46.1% (n=223) vs 58.3% (n=226) placebo @ 32wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
50.8% (n=223) vs 62.3% (n=226) placebo @ 40wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
55.5% (n=223) vs 64.2% (n=226) placebo @ 48wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
57.9% (n=223) vs 66.7% (n=226) placebo @ 52wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
18.3% (n=225) vs 22.6% (n=226) placebo @ 8wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
29% (n=225) vs 40.7% (n=226) placebo @ 16wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
36.7% (n=225) vs 51.1% (n=226) placebo @ 24wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
44.9% (n=225) vs 58.3% (n=226) placebo @ 32wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
51.8% (n=225) vs 62.3% (n=226) placebo @ 40wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
58.3% (n=225) vs 64.2% (n=226) placebo @ 48wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
58.8% (n=225) vs 66.7% (n=226) placebo @ 52wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
SGRQ Total -2.8 vs -3 placebo score @ 52wk100 mg
absolute change · score
NCT02105948 · Phase 3
show 9 more results
-3.2 vs -4 placebo score @ 52wk100 mg
NCT02105948 · Phase 3
-5 vs -3.1 placebo score @ 52wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
-3.3 vs -3.1 placebo score @ 52wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
65.5 vs 66.2 placebo score @ 4wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
64.3 vs 64.6 placebo score @ 8wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
64.3 vs 63.3 placebo score @ 12wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
64.3 vs 61.7 placebo score @ 24wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
61.2 vs 60.4 placebo score @ 36wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
60.7 vs 62.4 placebo score @ 48wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
CAT Total -0.8 vs 0 placebo score @ 52wk100 mg
absolute change · score
NCT02105948 · Phase 3
show 9 more results
-1 vs -0.4 placebo score @ 52wk100 mg
NCT02105948 · Phase 3
-1.6 vs -0.4 placebo score @ 52wk100 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.4 placebo score @ 52wk300 mg SC
NCT02105961 · Phase 3 · registry result, not featured evidence
22.3 vs 23.9 placebo score @ 4wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
23.6 vs 23.8 placebo score @ 8wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
23.6 vs 23 placebo score @ 12wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
23.5 vs 23.4 placebo score @ 24wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
22.8 vs 22.5 placebo score @ 36wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
22.3 vs 24 placebo score @ 48wk
NCT04075331 · Phase 2/3 · registry result, not featured evidence
Time to Hospital Readmission or Death 5.63 vs 5.93 placebo months @ 48wk
time to event · months
NCT04075331 · Phase 2/3 · registry result, not featured evidence · converted to months from 24.4 weeks as posted
All Cause Hospitalization 1.54 vs 1.77 placebo Hospital readmission @ 48wk
absolute value · Hospital readmission
NCT04075331 · Phase 2/3 · registry result, not featured evidence

+ 18 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Depemokimab's landscape · Mepolizumab's landscape